How a Chinese pharmaceutical firm has leapt to the front of the global race for a vaccine while the pandemic rages on

• CanSino Biologics is vaulting into the global spotlight as connections on both sides of the Pacific make it one of the front-runners in the race for a coronavirus vaccine
• In May, CanSino became the first globally to publish a full scientific study on its early human trials, an important step because it allows researchers worldwide to assess a vaccine’s potential